1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166. 

Voor meer informatie: http://www.quirem.com/

1st production QuiremSpheres

Other news

GMP-certificate received

GMP-certificate received

Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...

Read more

First liver cancer patient treated with microspheres irradiated in TU Delft

First liver cancer patient treated with microspheres irradiated in TU Delft

Radboud Translational Medicine will perform the dispensing of below product. The production and dis...

Read more

RTM receives marketing authorisation for Fludeoxyglucose (18F)

RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....

Read more

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.